EHMT2 and Alzheimer disease: As results, our proteomic data indicated that MS1262 treatment reversed or recovered the G9a-regulated, pathogenic expression or phosphorylation of specific proteins that represented AD-disturbed pathways related to learning and memory, cognition, neuronal functions, and non-cognitive behavior.